CoChat

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial

Open access

Abstract

Background: Antiangiogenesis tyrosine kinase inhibitors (TKIs) have been shown to prolong progression-free survival (PFS) in advanced osteosarcoma. Methylsulfonic apatinib is a TKI that specifically inhibits vascular endothelial growth factor receptor-2. We aim to assess apatinib in patients with advanced high-grade osteosarcoma progressing upon chemotherapy. Materials and Methods: This phase II trial was conducted at Peking University People's Hospital. We enrolled participants (≥16 years of age) with progressive relapsed or unresectable osteosarcoma. Participants received 750 mg or 500 mg of apatinib according to body surface area once daily until disease progression or unacceptable toxicity. The primary endpoint was objective response rate and PFS at 4 months. Results: A total of 37 participants were finally included into the analysis. Until final follow-up, the objective response rate (complete response + partial response) was 43.24% (16/37). The 4-month PFS rate was 56.76% (95% confidence interval [CI], 39.43%–70.84%). Median PFS and overall survival were 4.50 (95% CI, 3.47–6.27) and 9.87 (95% CI 7.97–18.93) months, respectively. Toxic effects led to dose reductions or interruptions in a total of 25 of 37 (67.57%) patients. The most common grade 3–4 adverse events were pneumothorax in six (16.22%) patients, wound dehiscence in four (10.81%), proteinuria in three (8.11%), diarrhea in three (8.11%), and palmar-plantar erythrodysesthesia syndrome in three (8.11%). No other serious adverse events were reported during the trial. There were no treatment-related deaths. Conclusion: Apatinib is a sensitive drug for advanced osteosarcoma with a high response rate after failure of chemotherapy, with similar duration of response compared to other TKIs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1634/theoncologist.2018-0542

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Research works printed but not linked: 1

  1. U.S. Department of Health and Human Services, 2010, Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03

Cited by

See all 128

Metadata

Authors
Xie, L., Xu, J., Sun, X., Tang, X., Yan, T., Yang, R., & Guo, W.
Affiliations
Peking University People's Hospital (CN)
Corresponding author
Guo, Wei
Venue
The Oncologist
Published
2018-12-17
Volume
24
Issue
7
Pages
e542-e550
ISSN
  • 1083-7159 (ISSN-L)
  • 1549-490X
OpenAlex
W2904481169
Cited by
128
References
31
Citations by year
2026: 8 · 2025: 12 · 2024: 12 · 2023: 14 · 2022: 26 · 2021: 27 · 2020: 21 · 2019: 7
FWCI
10.36
Type
journal article
Language
en
Open access
Locations
  • The Oncologist (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
Jiangsu Hengrui Medicine
Topics
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
  • Health Sciences › Medicine › Oncology › Vascular Tumors and Angiosarcomas
Keywords
apatinib, antiangiogenic tyrosine kinase inhibitors, VEGFR-2 inhibition, progression-free survival, objective response rate, adverse events, pneumothorax, chemotherapy-refractory disease, second-line therapy, overall survival, proteinuria, hand-foot syndrome
MeSH terms
Progression-Free Survival, Adolescent, Adult, Antineoplastic Agents, Female, Humans, Male, Middle Aged, Prognosis, Prospective Studies, Pyridines, Osteosarcoma, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial. https://app.cochat.ai/papers/10.1634/theoncologist.2018-0542
The paper
Xie, L., Xu, J., Sun, X., Tang, X., Yan, T., Yang, R., & Guo, W. (2019). Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial. The Oncologist. https://doi.org/10.1634/theoncologist.2018-0542

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.